Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 311Leukemia, Lymphocytic, Chronic, B-Cell 108Myelodysplastic Syndromes 63Recurrence 55Leukemia 43Neoplasms 42Precursor Cell Lymphoblastic Leukemia-Lymphoma 41Lymphoma, Non-Hodgkin 41Lymphoma, Mantle-Cell 32Multiple Myeloma 28Lymphoma, Large B-Cell, Diffuse 27Leukemia, Myelomonocytic, Chronic 27Lymphoma, Follicular 22Lymphoma 21Hematologic Neoplasms 20Lymphoma, B-Cell, Marginal Zone 18Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 17Leukemia, Biphenotypic, Acute 16Burkitt Lymphoma 16Myeloproliferative Disorders 11Lymphoma, B-Cell 11Leukemia, Myeloid 11Neoplasm, Residual 10Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10Waldenstrom Macroglobulinemia 9Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 7Chromosome 17 deletion 6Leukemia, B-Cell 5Immunoglobulin Light-chain Amyloidosis 5Breast Neoplasms 5

Interventions

Azacitidine 3venetoclax 1eprenetapopt 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myeloid Malignancy × venetoclax × Clear all
NCT04214860 2025-03-17

APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies

Aprea Therapeutics

Phase 1 Completed
51 enrolled 9 charts

Myeloid Malignancy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡